Investigational Drug Information for Ambroxol
✉ Email this page to a colleague
What is the development status for investigational drug Ambroxol?
Ambroxol is an investigational drug.
There have been 25 clinical trials for Ambroxol.
The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2007.
The most common disease conditions in clinical trials are Pharyngitis, Parkinson Disease, and Dementia. The leading clinical trial sponsors are Boehringer Ingelheim, Sanofi, and Hyundai Pharmaceutical Co., LTD.
Summary for Ambroxol
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 3,484 |
| WIPO Patent Applications | 1,686 |
| Japanese Patent Applications | 943 |
| Clinical Trial Progress | Phase 3 (2007-08-01) |
| Vendors | 78 |
Recent Clinical Trials for Ambroxol
| Title | Sponsor | Phase |
|---|---|---|
| Ambroxol as a Disease-modifying Treatment in GBA-PD | IRCCS National Neurological Institute "C. Mondino" Foundation | Phase 2 |
| Ambroxol as a Disease-modifying Treatment in GBA-PD | University of Campania "Luigi Vanvitelli" | Phase 2 |
| Ambroxol as a Disease-modifying Treatment in GBA-PD | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Phase 2 |
Clinical Trial Summary for Ambroxol
Top disease conditions for Ambroxol
Top clinical trial sponsors for Ambroxol
US Patents for Ambroxol
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
